While some analysts forecasted the tariffs could mean billions in additional industry expenditure, others expect the overall ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

In a post on X, Health Secretary Robert F. Kennedy Jr. alleged that the Vaccine Injury Compensation Program has “devolved ...

Six weeks after HHS Secretary RFK Jr. cited unexplained conflicts of interest in dismissing all 17 members of the CDC’s vaccine advisory committee, Democrats are asking for details.

The swift FDA action removes an overhang from Sarepta and allows Elevidys to return to the market without another safety ...

The star of GSK’s Hengrui partnership is the COPD candidate HRS-9821, which will complement the pharma’s respiratory pipeline ...

The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

The Commissioner’s National Priority Vouchers aim to offer accelerated pathways to drugs that meet certain criteria, perhaps ...

Despite the failure of its Recognify-partnered inidascamine, Jefferies analysts do not expect a definitively negative stock ...

These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up ...